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ABSTRACT
N-Oct-3 is a neuronal transcription factor widely
expressed in the developing mammalian central
nervous system, and necessary to maintain neural
cell differentiation. The key role of N-Oct-3 in the
transcriptional regulation of a multiplicity of genes
is primarily due to the structural plasticity of its
so-called ‘POU’ (acronym of Pit, Oct, Unc) DNA-
binding domain. We have recently reported about
the unusual dual neuro-specific transcriptional regu-
lation displayed by N-Oct-3 [Blaud,M., Vossen,C.,
Joseph,G., Alazard,R., Erard,M. and Nieto,L. (2004)
J. Mol. Biol., 339, 1049–1058]. To elucidate the under-
lying molecular mechanisms, we have now made
use of molecular modeling, DNA footprinting and
electrophoretic mobility shift assay techniques.
This combined approach has allowed us to uncover
a novel mode of homodimerization adopted by the
N-Oct-3 POU domain bound to the neuronal aromatic
amino acids de-carboxylase and corticotropin-
releasing hormone gene promoters and to demon-
strate that this pattern is induced by a structural
motifthatwehavetermed‘NORE’(N-Oct-3responsive
element), comprising the 14 bp sequence element
TNNRTAAATAATRN. In addition, we have been able
to explain how the same structural motif can also
induce the formation of a heterodimer in association
with hepatocyte nuclear factor 3b(/Forkhead box a2).
Finally, we discuss the possible role of the NORE
motifinrelationtoneuroendocrinelungtumorforma-
tion, and in particular the development of small
cell lung cancer.
INTRODUCTION
The coordinated expression of the 34604 genes annotated in
the human genome (1) is essential to the healthy development
and functioning of the organism. Regulation of gene expres-
sion is ensured by a complex network of transcription factors
that modulate the activity of RNA polymerase II by speciﬁc-
ally binding to promoter sequences upstream of the starting
point of transcription. Our understanding of the molecular
mechanisms involved in transcriptional regulation has evolved
considerably during recent years [reviewed in (2,3)], thus
providing a structural framework to analyze in detail a wide
spectrum of metabolic disorders, autoimmune diseases and
cancers, in relation to the inappropriate functioning of trans-
cription factors; such dysfunctions can, in general, be ascribed
to mutations that modify either the expression levels or the
functional structure of the factor [reviewed in (4–6)].
N-Oct-3, the human equivalent of the mouse Brn-2
(‘Brain-2’) protein, is a neuronal transcription factor widely
expressed in the developing mammalian central nervous sys-
tem, and necessary to maintain neural cell differentiation (7).
The deletion of the Brn-2 gene results in the loss of speciﬁc
neuronal lineages in the endocrine hypothalamus and
subsequent loss of the posterior pituitary gland (8–10). Any
imbalance in N-Oct-3 expression has critical consequences.
For example, N-Oct-3 over-expression in melanocytes, cells
derived from the neural crests, leads to tumorigenesis via the
dysregulation of a number of genes (11–14). The fact that
N-Oct-3 is such a key player in the regulation (and dysregu-
lation)of transcription ofso many genes isdue tothe structural
plasticity of its so-called ‘POU’ (acronym of Pit, Oct, Unc)
DNA-binding domain (DBD), which allows the recognition of
a whole array of DNA targets.
The POU family of transcription factors is deﬁned on the
basis of a common DBD of  160 residues, ﬁrst identiﬁed in
the mammalian proteins Pit-1 and Oct-1 and the nematode
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doi:10.1093/nar/gki284factor Unc-86 [reviewed in (15)]. The POU DBD comprises
two distinct, highly conserved sub-domains, termed ‘POUs’
and ‘POUh’, which contain four and three a-helices, respect-
ively, and are connected by a linker, variable in sequence and
length. All the POU domains bind speciﬁcally to the proto-
typic octamer ATGCAAAT. The crystallographic structure of
the complex between the POU domain of the ubiquitous pro-
tein Oct-1 and the octamer has revealed that POUs interacts
with the tetramer ATGC in a way similar to the phage repres-
sors, whereas POUh interacts with the tetramer AAAT in a
way similar to a homeodomain (16). Both sub-domains insert
their third a-helix, the so-called ‘recognition helix’, into
the DNA major groove. In addition, POUh inserts its rigid
N-terminal arm into the DNA minor groove via a speciﬁc
contact between a highly conserved arginine residue and
the ﬁrst adenine nucleotide of the AAAT sequence. Despite
the robustness of the ﬁt between a POU domain and the octa-
mer sequence, most POU domains can also recognize various
other AT-rich sequences owing to the ﬂexibility of the linker
joining the two sub-domains (17). To a certain extent, POUs
and POUh recognize the respective elements of a DNA target
relatively independently. These elements neither have to be
contiguous nor even to belong to the same strand of the DNA
(18). The extent of the adaptability of a POU domain to its
target is determined by the length and sequence of the variable
linker, which is speciﬁc to a given POU protein (19).
An important functional implication of the structural plas-
ticity of the POU domain is the possibility of different patterns
of homo and heterodimerization. So far, based on the crystal-
lographic structures of various Pit-1 or Oct-1 POU/DNA
complexes, two major types of POU homodimerization with
palindromic or pseudo-palindromic DNA targets have been
described previously (20). In previous reports, we have pre-
sented the characteristic patterns of N-Oct-3 binding to a
set of neuronal promoters, including the AADC (aromatic
amino acids de-carboxylase), CRH (corticotropin-releasing
hormone) and aldolase C gene promoters. We have observed
either an atypical homodimerization or a heterodimerization
with the hepatocyte nuclear factor HNF-3b, also referred to as
Forkhead box a2 (21,22). This alternative mechanism of tran-
scriptional regulation is impossible for Oct-1, which is only
able tobindasamonomertothesetargets.Wehave shownthat
this differential binding pattern of Oct-1 and N-Oct-3 could be
correlated with the unique capacity of a small segment of the
N-Oct-3 POU linker to adopt an a-helical structure (22).
The main objective of the present study is to elucidate the
molecular mechanisms underlying the unusual dual neuro-
speciﬁc transcriptional regulation found for N-Oct-3. A
detailed compilation of the available POU/DNA complex
structures, as well as a combination of molecular modeling,
DNA footprinting and electrophoretic mobility shift assay
(EMSA) have enabled us to (i) uncover a new mode of
homodimerization adopted by the N-Oct-3 POU domain
bound to the respective neuronal AADC and CRH gene pro-
moters, (ii) demonstrate that this pattern is induced by a novel
structural motif, the NORE (N-Oct-3 responsive element) and
(iii) understand how the same structural motif can also induce
the formation of a heterodimer in association with HNF-3b
DBD. Finally, we discuss the structure/function relationships
of the NORE motif in the context of neuroendocrine tumors,
and in particular small cell lung cancer (SCLC).
MATERIALS AND METHODS
Protein expression and purification
The N-Oct-3 and HNF-3b DBDs were expressed in
Escherichia coli and puriﬁed as reported previously (21).
Oligonucleotides and DNA-binding assays
Twenty-four base pair oligonucleotides corresponding to the
( 95/ 72) and ( 127/ 104) fragments of the human
neuronal AADC gene promoter (23) and the rat CRH gene
promoter (24), respectively, and encompassing the N-Oct-3
POU homodimer binding sites (22), served as ‘wild-type’ ref-
erences for a whole range of derived mutations. The double-
stranded oligonucleotides were prepared and EMSA carried
out as described previously (21,22).
DNase I and copper-phenanthroline footprinting
A vector plasmid (pRA103) carrying the  176 to  92 region
of the rat CRH promoter (24) was constructed. A 122 bp
fragment encompassing this CRH promoter sequence was
then generated by PCR using ﬂanking primers and puriﬁed
on a 10% polyacrylamide gel.
The
32P-end-labeled CRH DNA fragment (5 nM concentra-
tion)wasincubatedat28 Cfor30minwithincreasingamounts
of N-Oct-3 DBD (3.2–16 nM concentration range) in 20 ml
binding buffer (25 mM Tris, pH 7.5, 6% glycerol, 125 mg/ml
BSA,0.5mMEDTA,5mMMgCl2,100mMNaCl,2mMDTT
and 0.004% Tween-20). DNase I footprinting assays were
carried out according to the standard protocols (25).
1,10-phenanthroline-copper ion (OP2-Cu) footprinting
experiments were performed as described by Kuwabara and
Sigman (26). The protein/DNA complexes were ﬁrst separated
on a 5% polyacrylamide gel and the DNA then cleaved within
the gel. In both types of footprinting experiments, products
ofthe Maxam–Gilbert chemicalcleavage reaction ofthe ident-
ical PCR fragment served as sequence references (27).
Molecular modeling
Modelsweregeneratedusingthe‘Accelrys’modulesInsightII,
Biopolymer, Discover, Docking and Homology (version
2000.1),runonaSiliconGraphicsFuelworkstation.Thestruc-
tures of the N-Oct-3 POUs and POUh sub-domains were built
by homology to the Oct-1 POU sub-domains [PDB accession
no. 1OCT (16)] as described previously (21). Similarly, the
HNF-3b DBD structure was based on that of HNF-3g DBD
[nucleic acid data bank (NDB) accession no. PDT013 (28)].
Models of the 18 bp DNA fragments from the osteopontin
and immunoglobulin G (IgG) VH gene promoters were built
using their respective homology with the PORE and MORE
motifs of known 3D structures [PDB accession nos 1HF0 and
1E3O (20)]. Models of the 18 bp DNA fragments from the
AADC and CRH gene promoters were built based on local
homology with the octamer DNA and the HNF-3g target DNA
(PDB and NDB accession nos 1OCT and PDT013). The inter
base pair structural parameters (rise, twist, tilt and roll)
inferred from the homologous crystallographic templates
were found in the ‘Double-helix/Bending Analysis’ database
ﬁles(http://www.imb-jena.de)establishedwiththe‘CURVES’
algorithm (29). These values served as input for the Bio-
polymer module.
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docked into the sub-sites of the 18 bp DNA fragments, based
on homology with the respective complex crystallographic
structures cited above. The structure of the linker between
the POUs and POUh sub-domains was built as described
previously (21), and in all cases including the a-helical
structure of the IDKIAAQ segment served as a constraint.
The resulting preliminary structures were then submitted to
the ‘Afﬁnity’ program, an automatic docking reﬁnement pro-
cedure within the Docking module which follows a Monte
Carlo interaction energy minimization protocol and allows
ﬂexibility to predeﬁned atoms of both the ligand-DBD and
receptor-DNA.
RESULTS AND DISCUSSION
Structural lessons from the two prototypic PORE and
MORE modes of POU domain homodimerization
and their relevance to N-Oct-3
To date, the two major modes of POU domain homodimeriza-
tion are generic, and are induced by two types of DNA
sequence,theso-called‘PORE’(palindromicOct-1responsive
elements) and ‘MORE’ (more palindromic Oct-1 responsive
elements) sequences, respectively. The prototypic PORE
sequence ATTTGAAATGCAAAT (Figure 1A, sequence 1) is
an element of the osteopontin gene enhancer (30,31). The abil-
ity to induce a distinct type of Oct-1 POU homodimerization
Figure 1. The three generic modes of N-Oct-3 POU domain homodimerization. (A) Eighteen base pair DNA sequences of: (1) the osteopontin gene enhancer
fragment defining the PORE motif, (2) the prototypic MORE motif, (3) the MORE-type IgG VH gene promoter canonical fragment and (4) the AADC gene
promoter fragment defining the new NORE motif. In all the cases, the first and second N-Oct-3 POU domain binding sites are coded in brown and turquoise,
respectively.InthePORE(1)andNORE(4)motifs,criticalnucleotidesofthefirstandsecondPOUhtetramericsub-sitesarecodedinredandindigorespectively.In
theMOREmotifs(2and3),thefirstandsecondPOUhtetramericsub-sitesareunderlinedinbrownandturquoise,respectively,tocompensatefortheoverlapwiththe
POUsbindingsub-sites.(B–D)ModeledstructuresofthehomodimericcomplexesbetweentheN-Oct-3DBDand(B)aPOREmotif(sequence1),(C)aMOREmotif
(sequence3)and(D)aNOREmotif(sequence4).Inallthecases,therespectivedisplay-codesforthefirstandsecondN-Oct-3POUdomainsareasfollows:brown-
andturquoise-coloredcylindersforthea-helices,red-andindigo-coloredarrowsforthePOUhrecognitionhelices,darkbrown-andblue-coloredcoilsforthelinkers.
InthePORE(B)andNORE(D)typesofcomplexes,thefirstandsecondPOUhN-terminalextensionsaredisplayedasred-andindigo-coloredribbons,respectively,
their insertion into the DNA minor groove being indicated by asterisks of the identical color.
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ated by a single T–G nucleotide transition, and the crystallo-
graphic structure oftheresultingcomplexhasbeen determined
(20). The N-Oct-3 DBD can also homodimerize with the nat-
uraltargetasjudgedbyEMSAandcirculardichroism(datanot
shown), and we have modeled the structure of the correspond-
ing complex by homology to that of the Oct-1 POU/PORE
complex (Figure 1B). In this conﬁguration, the relative posi-
tioningofPOUsandPOUhwithineachmonomerisidenticalto
that found in the prototypic Oct-1 POU/octamer complex.
The prototypic MORE sequence ATGCATATGCAT is a
palindromic synthetic sequence (Figure 1A, sequence 2),
which induces a different homodimerization pattern of the
Oct-1 POU domain, as revealed by crystallography of the
corresponding complex (20). In this case, the POUs of one
monomer interacts with the ATGC tetramer on one strand,
while its POUh counterpart interacts with the GCAT tetramer
on the opposite strand. This type of homodimerization is not
restricted to the Oct-1 DBD, as illustrated previously by the
crystallographic structures of Pit-1 POU homodimers formed
with various synthetic or natural promoter sequences (18,32).
The most unexpected example of a ‘natural’ MORE sequence
is no doubt provided by the previously termed ‘heptamer–
octamer’canonicalsequencefromthehumanimmunoglobulin
heavy chains gene promoters (IgG VH) (Figure 1A, sequence
3). The demonstration that this motif is in fact a MORE
sequence (31) revealed an even more pronounced sequence
degeneracy for the ﬁrst and second POUh binding sites, TCAT
and GCAA, respectively, in contrast with the prototypic tet-
ramer AAAT. We have previously reported that the N-Oct-3
DBD homodimerizes cooperatively with this canonical target
(21,22). N-Oct-3 DBD also binds to the prototypic MORE
sequence, even more cooperatively, which is coherent with
the perfect symmetryofthetwobinding sites(datanotshown).
Bearing in mind that the overall structures of the two homodi-
meric complexes will be similar when induced by structurally
equivalent targets, we have modeled the interaction between
the N-Oct-3 DBD and the canonical sequence by homology
to the known structure of the Oct-1 POU/MORE complex
(Figure 1C). The relative positioning of the POUs and POUh
sub-domains within each monomer is clearly very different
from that in the PORE mode (Figure 1B). This is owing to the
relative positioning of the tetrameric binding sites, which are
non-contiguous and on opposite strands in the MORE mode
(Figure 1A, sequence 3), as opposed to contiguous and on the
same strand in the PORE mode (Figure 1A, sequence 1).
One of the main lessons that can be drawn from the detailed
analysis of the atomic structures of the different POU
homodimer/DNA complexes is the paramount importance
of the underlying structural symmetry of the DNA sequences
involved. Thus, depending on the structural context in which it
is embedded, the octamer sequence ATGCAAAT will be read
by a POU domain in two totally different ways. In the PORE
mode, it will be interpreted as a continuous POU binding site,
while in the MORE mode, it will be segmented into the POUs
binding site (ATGC) for one monomer and the overlapping
POUh binding site for the other monomer (GCAA), the
terminal AT being ‘mute’. The prominence of ‘structure’
over ‘sequence’ explains the signiﬁcant sequence degeneracy,
which is generally observed in the POU binding sites, often
making it very difﬁcult to identify a simple consensus.
Another source of sequence degeneracy in the POU homo-
dimer binding site is related to the way homodimeric ternary
complexes achieve stability. An important component of
stability is obviously the strength of the interaction between
the two DBDs, which lessens the need for stringent contacts
between all the POU sub-domains and the target DNA. Thus,
in order to function as a PORE motif, a given sequence needs
onlydisplay two well-conservedand symmetrically positioned
POUhbindingsites, sincea certain amount of sequence degen-
eracy is allowed for the POUs binding sites. The converse is
true for a MORE motif.
The N-Oct-3 DBD is thus emblematic of the adaptability
of a POU domain to a variety of targets. In addition to the
set of neuronal promoters with which it homodimerizes non-
cooperatively (22), N-Oct-3 also forms cooperative homo-
dimers in association with PORE sequences and with MORE
sequenceswhichincludethecanonicaltarget.Evenifthenatural
gene enhancer and promoter (osteopontin and IgG VH)
described here are probably not relevant to N-Oct-3 function
in vivo, they can serve as model targets to probe the structural
plasticityofN-Oct-3DBD.Indeed,wehaveexperimentalevid-
ence that several promoter targets deregulated by N-Oct-3 in
melanoma cells might be MORE sequences (R. Alazard,
L. Nieto and M. Erard, unpublished data). If the N-Oct-3
DBD can adopt the same homodimerization patterns as Oct-1
DBD, the reverse is not true. Thus, the Oct-1 POU domain can
only bind as a monomer on the same set of neuronal promoters
which induce a non-cooperative N-Oct-3 POU homodimeriza-
tion.Ourobjective, therefore, istodecipher thestructuralbasis
of this third pattern of N-Oct-3 DBD homodimerization and
compare it with the PORE and MORE binding modes.
Similar structural elements in the neuronal
AADC and CRH gene promoters induce a novel
homodimerization pattern of the N-Oct-3 POU
domain, the ‘NORE’ mode
We have previously identiﬁed the binding site of the ﬁrst
N-Oct-3 DBD monomer to the neuronal AADC gene pro-
moter, namely AAATAATGC, and modeled the correspond-
ing binary complex (21). In this case, the respective targets of
the POUh and POUs sub-domains are separated by a single
nucleotide and in a so-called ‘switched’ order relative to the
consensus octamer. This gives rise to a positioning of the ﬁrst
monomer (Figure 1D) which is different from that observed in
the PORE or MORE complexes (Figure 1B and C). However,
the principle nucleotides in contact with the POUh and POUs
sub-domains are located on the same DNA strand, a feature in
common with a PORE-type binary complex (Figure 1A, com-
pare the respective upper strands in sequence 1 and 4). In order
to determine the binding site for the second monomer, which
is likely to be located on the opposite strand, we introduced
triplet mutations into the 24 bp fragment of the AADC
promoter and probed the homodimeric interaction with the
N-Oct-3 DBD using EMSA (Figure 2A). Note that only the
results relating to the 18 bp core fragment are presented, with
nucleotides numbered accordingly (the ﬁrst and last base
pairs are colored in blue). Strikingly, mutations of the triplets
T8A9A10 and T12A13A14 to GCC (mutants 4 and 6, respect-
ively) aredeleterioustobothbindingsites,with mutant4being
the most affected. Thus, structural elements critical to both
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lap within the TAAATAA motif of the wild-type AADC pro-
moter. Since the ﬁrst monomer POUh sub-domain not only
inserts its recognition helix into the A9A10A11T12 tetramer
major groove but also tightly anchors into the minor groove
via a canonical contact between the conserved Arg 93 residue
in the rigid arm and the Ade 9 nt (Figure 2B), the most obvious
candidate for the second POUh overlapping and symmetric
binding site is the A7BT8BT9BT10B motif on the opposite
strand.
Following this reasoning, we then modeled the homo-
dimeric ternary complex according to this likely positioning
of the second DBD (Figure 1A, sequence 4) and the resulting
structureisdisplayedinFigure1D.Inadditiontoprovidingthe
essential contact in the DNA minor groove between the con-
served Arg 93 residue from the POUh rigid arm and Ade 7B,
as well as the canonical van der Waals contact in the major
groove between the conserved Val 135 residue from the POUh
recognition helix and the methyl group of Thy 10B, this model
also predicts a second van der Waals contact between the
same Val 135 and the methyl group of Thy 9B (Figure 2C).
This partially compensates for the loss of the canonical double
hydrogen bond in the major groove between the conserved
Asn 139 of the recognition helix and Ade 11 (compare
Figure 2. StructuraldeterminantsoftheN-Oct-3POUhomodimerizationontheAADCgenepromoter(A)Mutationscanningofthe18bpcoreregionoftheAADC
fragment(thefirstandlastbasepairsarecoloredinblue)wascarriedoutbyselectinginturn8overlappingnucleotidetriplets,inwhichAandGweresubstitutedbyC,
and C and T substituted by G. The interactions between the N-Oct-3 DBD and the mutated AADC fragments were analyzed by EMSA and compared with
the interaction with the non-mutated sequence (WT). The two most critical triplet mutations and their corresponding EMSA patterns have been highlighted.
(B) Canonical interaction between the first monomer POUh and the optimal AAAT sub-site: anchoring into the DNA minor groove via the Arg 93/Ade 9 contact
(redasterisk)andinsertionoftherecognitionhelixintothemajorgrooveviatheAsn139/Ade11andVal135/Thy12contacts(pinkarrow).(C)Interactionbetween
the second monomer POUh and the ATTT sub-site: anchoring into the DNA minor groove via the Arg 93/Ade 7B contact (indigo asterisk) and insertion of the
recognitionhelixintothemajorgrooveviathehydrophobiccontactsbetweenVal135andbothThy9BandThy10B(turquoisearrow).(D)LocationofArg93(inred
box), Val 135 (in turquoise box) and several important residues within the secondary structure elements of the first (POU1) and second (POU2) DBDs. Respective
colorcodingisasfollows:a-helicesinbrownandturquoise;POUhN-terminalextensionsinredandindigo;linkersindarkbrownandblue.POUs1Gln40,Thr41and
Arg 45 are colored in red, and POUs2 Thr 41 and Arg 45 in white.
Nucleic Acids Research, 2005, Vol. 33, No. 5 1517Figure 2C with 2B). In this conﬁguration, the second POUs
recognition helix is inserted into the C12BT13BG14BA15B
tetramer major groove, thus generating a hydrophobic contact
between the conserved Thr 41 and Thy 4 (paired with A15B),
and a hydrogen bond between the Arg 45 side chain and
Thy 13B (see their respective locations in the nucleotide
sequence in Figure 2C and in the ‘POU2’ amino acid sequence
in Figure 2D). In contrast, as previously shown (21), the ﬁrst
POUs inserts its recognition helix into the ATGC tetramer
major groove, allowing the canonical interactions between
the conserved Gln 40, Thr 41 and Arg 45 side chains and
Ade 14, Thy 15 and Gua 16, respectively (see their respective
location in the nucleotide sequence in Figure 2B and in the
‘POU1’ amino acid sequence in Figure 2D).
In order to determine whether this novel mode of N-Oct-3
POU homodimerization can also be elicited by the CRH
promoter, we carried out DNAse I footprinting experiments.
Our results show that the binding of the ﬁrst monomer mainly
protects the upper strand, with a clear footprint visible over
the AAATAATAG sequence (Figure 3A, lane 4). This is
consistent with the homology (78%) to the high-afﬁnity
binding site (AAATAATGC) on the AADC promoter (see
the respective upper strands in the Figure 4A alignment).
On the other hand, the binding of the second DBD is necessary
to observe complete protection of the lower strand ATTA-
TTTATGCA sequence (Figure 3B, lanes 5 and 6) and of
the CCTGCAT sequence on the 50 side of the upper strand
(Figure 3A, lanes 5 and 6). To further identify the structural
elements common to both promoters, we also performed
a triplet mutation scanning of the 24 bp fragment of
the CRH promoter. The results for triplet mutation scanning
of the CRH promoter fragment were very similar to those
already described for the AADC promoter (data not shown),
and most importantly the conversion of the central TAA
triplet to GCC virtually abolished the binding of both mono-
mers (Figure 4B). These results again imply overlapping
symmetric binding sites for the two POUh sub-domains
(see Figure 4A). Moreover, the subsequent positioning of
the second POUs sub-domain is entirely consistent with the
total DNAse I protection observed for the lower strand
ATTATTTATGCA sequence following the binding of the
second monomer (Figure 3B).
We then made use of these results as topological constraints
in order to model the homodimeric complex. Figure 4C and D
display a front view of the ﬁrst and second POUh domains
binding to their respective AAAT and ATTT tetrameric
targets. Important features to note are the anchoring of the
Arg 93 residues into the DNA minor groove, and the insertion
of the recognition helices (indicated by red- and purple-
colored arrows) into the DNA major groove via the Asn
139 and Val 135 residues for the ﬁrst-bound DBD POUh
and via Val 135 alone for the second-bound POUh. Again,
the insertion of the ﬁrst POUs recognition helix (indicated by a
red triangle in Figure 4C) in the ATAG tetramer is ensured by
the highly conserved Gln 40, Thr 41 and Arg 45 (see their
location within the ‘POU1’ amino acid sequence in
Figure 4E). As for the AADC promoter-induced complex,
Thy 4 (whose location is indicated by a red asterisk in
Figure 4C and D) is critical to the insertion of the second
POUs recognition helix (purple triangle in Figure 4D) by
allowing a hydrophobic contact with the Thr 41 methyl group.
The mutation of this key nucleotide indeed abolishes the
binding of the second monomer (data not shown).
We have coined the term ‘NORE’ to designate the 14 bp
sequence element TNNRTAAATAATRN (N: any nucleotide
and R: purine residues), which is common to the neuronal
AADC and CRH gene promoters and capable of eliciting a
novel homodimerization mode exclusive to the N-Oct-3 DBD.
Both the NORE and PORE motifs elicit a ‘POUh-dominant’
mode of N-Oct-3 DBD homodimerization (Figure 1D).
However, in the case of the NORE mode, the two POUh
binding sites are overlapping, thus creating a symmetrical
‘center’ relative to the position of the two POUs sub-
domains (Figure 4C and D). This generates a unique interface,
not only between the two POUs sub-domains, but also, and
of equal importance, between the a-helical linker regions. In
this context, we have established a strict correlation between
the absence of the IDKIAAQ motif in the Oct-1 POU
domain linker and its inability to form homodimers with
the neuronal AADC, CRH or aldolase C gene promoters
(22). Since there is an order of magnitude difference between
the apparent afﬁnity constants for N-Oct-3 DBD interacting
with the two binding sites of these neuronal promoters, it is
likely that the interaction energy between the two DBDs is
an important component of homodimeric complex stability.
Although we have already alluded to this in the case of the
PORE and MORE complexes, it is only in the NORE mode
that the N-Oct-3 POU linkers are in the appropriate position
relative to each other to stabilize the protein/protein interface
(Figure 1B–D).
Figure3. DNAseIfootprintinganalysisofN-Oct-3POUhomodimerizationon
the CRH gene promoter. Autoradiograms of 12% polyacrylamide denaturing
gels showing the DNAse I footprints on the upper (A) and lower (B) strands of
the CRH promoter fragment. Lanes 1 and 2, Maxam–Gilbert chemical sequen-
cing references (cleavage after pyrimidine and purine residues, respectively).
Lane 3, free DNA cleavage products. Lane 4, first DBD footprint (brown color
coding). Lanes 5 and 6, POU homodimer footprint (blue color coding).
1518 Nucleic Acids Research, 2005, Vol. 33, No. 5NORE, a novel structural motif and a dual
transcription factor binding site
Interestingly, the alignment of the homologous N-Oct-3 DBD
binding sites present within the CRH and AADC promoters
reveals another type of homology. The 4 nt, T4, A7, T8 and
A10 of the CRH promoter are indeed homologous to T4,
G7, T8 and A10, known to structurally specify the binding
of HNF-3b on the AADC promoter [see the pink-coded
nucleotides in the sequences 1 and 2 in Figure 5A and (21)].
In fact, for both promoters the HNF-3b binding site overlaps
that of the ﬁrst N-Oct-3 POU domain, deﬁning a composite
‘POU-HNF’ binding site. By using the EMSA approach, we
previously demonstrated that the N-Oct-3 and HNF-3b DBDs
could simultaneously bind to the neuronal AADC, CRH
and aldolase C genes promoters, despite the overlap in their
binding sites (22). Furthermore, we were able to build a model
of the heterodimeric complex formed on the 18 bp AADC
promoter fragment (21).
We now present a model of the ternary complex formed
by the two DBDs and the 18 bp CRH promoter fragment
(Figure 5B). While the N-Oct-3 DBD occupies the
Figure 4. StructuraldeterminantsoftheN-Oct-3POUhomodimerizationontheCRHgenepromoter.(A)Alignmentofthe18bpcoreregionsoftheCRH(sequence
1)andAADC(sequence2)promoterfragmentsbasedonthehomologybetweentherespectivehigh-affinitybindingsitesforN-Oct-3DBD.Samecolorcodingasin
Figure 1A. (B) Conversion of the TAA triplet (in boldface) of the 24 bp CRH promoter fragment (‘WT’) GCTCCTGCATAAATAATAGGGCCC to GCC (mutant
‘DM’) and EMSA analysis of the differential binding pattern of the N-Oct-3 DBD to the two oligonucleotides. (C and D) Modeled structure of the homodimeric
complex between the N-Oct-3 DBD and the 18 bp CRH promoter fragment (sequence 1). Front views focusing on the first (C) and second (D) POU domain
interactionswithDNA.Seethetextforadetaileddescription.SamecolorcodingasinFigure1B–D.The‘footprints’onbothstrandsofthefirstandsecondDBDsare
shownasbrownandpurple-coloredConnollysurfaces,respectively.(E)SamecommentandcolorcodingasinFigure2D,exceptforPOUs1Gln40,Thr41andArg
45 colored in yellow, and POUs2 Thr 41 and Arg 45 in red and white, respectively.
Nucleic Acids Research, 2005, Vol. 33, No. 5 1519Figure5.IdentificationoftheNOREasastructuralmotifanddualtranscriptionfactorbindingsite.(A)StructuralhomologybetweentheHNF-3bbindingsitesonthe
CRH (sequence1) and AADC(sequence 2)gene promoters(pink-codednucleotides)and overlapwiththe N-Oct-3high-affinity bindingsites. Sequence3, optimal
NORE motif(N: any nucleotideand R: purine residues). Sequence 4, 18 bp core of the aldolase C gene promoterfragment. Sequence 5, extended consensusNORE
motifanditsdualbindingcapacityspecifyingN-Oct-3DBDhomoorheterodimerization(W:AorT).(B)Modeledstructureoftheheterodimericcomplexbetween
the N-Oct-3and HNF-3b DBDsandthe 18bp CRHpromoter.Notethe twomajorcomponentsofHNF-3b bindingandstructuralsimilaritieswiththesecondPOUh
bindinginthehomodimericcomplex.Seethetextforadetaileddescription.Display-codefortheDNAandN-Oct-3DBDasinFigure4CandD,andfortheHNF-3b
DBDasfollows:a-helicesareturquoise-coloredcylinders,b-strandsaredarkblueribbons,and‘wings’arebluecoils.(C)Locationoftheimportantresidueswithin
the secondary structure elements of HNF-3b DBD (‘HNF3B’); color coding as in (B). (D) Autoradiograms of 12% polyacrylamide denaturing gels showing the
OP2-Cu cleavage products of the upper (‘US’) and lower (‘LS’) strands of the CRH promoter fragment. Lanes 1 and 2, Maxam–Gilbert chemical sequencing
references (cleavage after pyrimidine and purine residues, respectively). Lanes 3, free DNA; cleavage enhancement sites highlighted in red. Lanes 4, DNA in the
1/1 high-affinity complex with the N-Oct-3 DBD; footprint and flanking cleavage enhancement sites highlighted in brown and green, respectively. (E) Model
of the bound-form of the NORE motif [same color coding as in (A), sequence 5].
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dimer,thetwomajor componentsofHNF-3bDBDbindingare
(i) the insertion of its third helix (indicated by a purple-colored
arrow) into the DNA major groove—mainly via the Asn 56/
Ade 10 double hydrogen bond contact and (ii) the interaction
in the minor groove between the HNF-3b C-terminal ‘wing’
Arg 101 and Thy 4 (Figure 5C, see the location of amino acid
residues). Our modeling reveals striking global similarities
between the binding of the HNF-3b DBD to the DNA in the
heterodimeric complex and the binding of the second N-Oct-3
POUh in the homodimeric complex (compare Figure 5B with
Figure 4D). In particular, it is worth underlining the critical
importance of Thy 4 (marked by a red asterisk) in both
contexts. Interestingly, the relative interchangeability of the
N-Oct-3 and HNF-3b DBDs with respect to the formation of a
structural ternary complex is in agreement with competitive-
binding EMSA experiments and in addition the DNA bending
is the same in both ternary complexes as shown by circular
permutation assays (data not shown).
Thus, not only can the NORE motif TNNRTAAATAATRN
(Figure 5A, sequence 3) elicit a novel type of N-Oct-3 DBD
homodimerization, but it can also induce heterodimerization
with the HNF-3b DBD. As is the case for the PORE and
MORE motifs, the underlying structure of the NORE motif
must play a fundamental role in its function. We have used
copper bis-phenanthroline as a probe to monitor the structure
of the CRH promoter fragment, either free or in complex with
a single molecule of N-Oct-3 DBD. Beyond its primary role as
a chemical agent for footprinting, copper bis-phenanthroline
has proved to be a powerful reporter for identifying local DNA
structure (33). Upon intercalation of its two phenanthroline
rings into the DNA minor groove, this drug cleaves both DNA
strands on either side with an efﬁciency which is sequence-
dependent (34). As shown in Figure 5D (lanes 3), the free
DNA is preferentially cleaved at two sites, the AAATAATAG
sequence in the upper strand and the ATTATTTATGCA
sequence in the lower strand, with hot spots at A9 and A13
and A4BT5B and A7BT8B, respectively, with numbering
referring to the 18 bp core fragment. Signiﬁcantly, these
hypersensitive sites map to the identical region as seen for
the footprint created by the binding of a single N-Oct-3 DBD
monomer as shown in lanes 4. This clearly implies that it is the
speciﬁc DNA minor groove structure of the NORE motif core
sequence TAAATAAT that directs the binding of the ﬁrst
DBD. A striking consequence of this binding is the enhance-
ment of nucleotide cleavage at C2C3T4, and in particular an
increasedaccessibilitytothecriticalThy4,thereby facilitating
binding of either the POUs of a second N-Oct-3 DBD or the
second wing of HNF-3b DBD.
Interestingly, the neuronal aldolase C gene promoter stimu-
lates the same pattern of N-Oct-3 binding as the AADC and
CRH promoters [(22) and C. Vossen, G. Joseph, L. Nieto and
M. Erard, unpublished data] although the nucleotides in posi-
tions 4and 12 of the aldolase C NORE motif are a thymine and
anadenine residue,respectively,insteadofpurineandthymine
residues (Figure 5A, see the white-coded nucleotides in the
sequence 4). In the context of N-Oct-3 POU homodimer
formation, both nucleotide changes fall within the POUs bind-
ing sites, which are unlikely to affect POUh-driven homodi-
merization in the NORE mode. In the case of heterodimer
formation, the purine in position 4 stacks with the Phe residue
of the HNF-3b DBD recognition helix and it can probably be
replaced by a thymine nucleotide. This again emphasizes that
the most critical mutations affecting function are the ones
which occur in the TAAATAA core sequence of the NORE
motif. In conclusion, the structural reading of the extended
consensus 14-residue NORE motif and the predicted 3D struc-
ture of its bound form are displayed in Figure 5A (sequence 5)
and Figure 5E, respectively.
Potential role of the NORE motif in
SCLC dysregulation
Based on its properties, the NORE motif can clearly be quali-
ﬁed as a so-called ‘composite element’ (CE). This notion was
ﬁrst introduced by Diamond et al. (35), who showed that the
glucocorticoid response element comprised a glucocorticoid
receptor binding site adjacent to an AP-1 binding site. Since
then, the concept has gained importance, leading to the estab-
lishment of the TRANSCompel dedicated database, which
now contains several hundreds of CEs (36). As deﬁned by
Makeev et al. (37), a CE corresponds to a pair of adjacent,
or even overlapping, binding sites, involved in the formation
of speciﬁc ternary complexes. It deﬁnes a minimal functional
unit in which both protein–DNA and protein–protein interac-
tions contribute to a speciﬁc pattern of gene transcriptional
regulation, and identical CEs are expected to perform related
functions in genes. Thus, the regulatory regions of the FGF-4,
UTF1 and Sox-2 genes, all involved in the maintenance of the
pluripotent state of embryonic stem cells, share a CE which
speciﬁes the co-binding of the Oct-3/4 and Sox-2 transcription
factors to adjacent sites (38–40). Regarding the AADC, CRH
and aldolase C gene neuronal promoters, we can ask what
is the potential function/dysfunction speciﬁed by the NORE
motif as a CE?
‘HNF-3b’hasrecentlybeenrenamed‘Foxa2’,thusreferring
rather to the presence of the highly conserved winged-helix
DBD than to any particular cellular localization. Deregula-
tion of human HNF-3(/Fox) genes leads to a whole range
of diseases, including congenital disorders, diabetes mellitus
and carcinogenesis (41). As reviewed by Costa et al. (42),
mouse HNF-3b is ﬁrst expressed shortly after the onset of
gastrulation in the foregut and visceral endoderm, the noto-
chordal mesoderm and the neurotube ﬂoorplate, and then
during the formation of the deﬁnitive endoderm. The adult
mouse expression pattern of HNF-3b includes epithelial
cells of the lung, liver, thyroid gland, pancreas, stomach and
intestine (42). Expression proﬁling techniques have revealed
that human HNF-3b can regulate complex networks of target
genes, such as those involved in insulin secretion (43) or in
lung epithelial cell maturation (44).
Most importantly, HNF-3b(/Foxa2) expression has very
recently been detected in the whole spectrum of human
neuroendocrine lung tumors, while it is absent from normal
pulmonary neuroendocrine (PNE) cells (45). Among the
neuroendocrine lung tumors expressing HNF-3b, SCLC is
currently the object of extensive research [reviewed in
(46–48)]. Classic SCLC cell lines are characterized by the
presence of several neuroendocrine markers, such as chromo-
granin A and AADC, and very high amounts of AADC mRNA
have been detected by RT–PCR (49). Derived from neuroecto-
dermal cells, SCLC expresses N-Oct-3, as well as a number of
Nucleic Acids Research, 2005, Vol. 33, No. 5 1521neuropeptides and their receptors (50). Thus, elevated CRH
levels have been observed in SCLC (51), with a subsequent
increase in cyclic AMP levels, arachidonic acid release and
lung cancer cell growth (52). Finally, the ectopic expression of
aldolase C in neuroendocrine tumors, including SCLC, has
been reported (53). In the light of these different observations,
we propose that the NORE motif, shared by the AADC, CRH
and aldolase C gene promoters, becomes functional as a
composite N-Oct-3/HNF-3b binding site, following the
appearance of HNF-3b expression, characteristic of SCLC
dysregulation. In contrast, in the normal PNE cells, N-Oct-3
wouldexist asahomodimer boundtotheNOREmotif,leading
to a basal level of expression of the AADC, CRH and aldolase
C genes. An example where the N-Oct-3 homodimer has a
reduced capacity to mediate transcriptional activation has
been reported previously (54).
CONCLUSION
The capacity to successfully predict transcription factor bind-
ing sites within promoters and potential synergies between
adjacent sites and bound factors is a major objective in the
post-genomic era (55,56). An essential prerequisite for this
is without doubt the need for a better understanding of the
complex mechanisms involved in transcriptional regulation.
As thoroughly reviewed by Johnson and Jameson (4), critical
parameters include the homo and heterodimerization of tran-
scription factor DBDs. Well-known examples are the nuclear
receptors and the basic leucine zipper (‘b-Zip’) proteins (57–
59), and the palindromic [or more often pseudo-palindromic
(60)] characteristics of their respective binding sites. In this
context, our study emphasizes the necessity (i) to employ a
structural as opposed to a purely linear sequence-based read-
ing of the nucleic regulatory sequences [reviewed in (61)] and
(ii) to take into account the often sophisticated ‘combinatorial
code’ used to achieve cell-speciﬁc gene expression (4).
Owing to its remarkable plasticity, the N-Oct-3 POU
domain can adopt three different conﬁgurations and corres-
ponding homodimerization patterns, with the POUs and POUh
sub-domains acting as sensors for the distinct structures which
characterize the respective PORE, MORE and NORE DNA
motifs. We have experimental evidence that, in solution, the
N-Oct-3 DBD is monomeric and without any preferential
conﬁguration (unpublished data). This implies that it is the
pre-existing DNA conformation that dictates the mode of
interaction with N-Oct-3 by providing a particular distribution
of potential POUs and POUh tetrameric binding sites. Indeed,
a number of recent articles have reassessed the so-called
‘indirect’ (i.e. structure-based) recognition mechanism as an
important determinant of speciﬁcity (62–64).
The NORE motif, present in a set of neuronal promoters,
elicits a particular type of POU domain homodimerization or
heterodimerization with HNF-3b, which is exclusive to the
neuronal transcription factor N-Oct-3. Interestingly, it is the
joint action of a structural DNA motif and a unique a-helical
structure adopted by part of the N-Oct-3 POU linker that
provides the basis for this alternative neuro-speciﬁc transcrip-
tional regulation. This process possibly involved in SCLC
might also be relevant to other types of neuroendocrine
tumors, for which HNF-3b expression clearly needs to be
investigated.
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